KALA BIO to Build On-Premises AI Platform
KALA BIO announced a strategic initiative to build an on-premises AI infrastructure platform for the biotech industry. The platform, "Researgency," is designed to be deployed directly within a client's own environment, allowing companies to use AI on proprietary data securely.
This strategic pivot follows a major setback in September 2025, when KALA BIO's lead drug candidate for a rare eye disease, KPI-012, failed to meet its primary endpoint in a Phase 2b clinical trial. Following the trial's failure, the company discontinued the development of its entire mesenchymal stem cell secretome (MSC-S) platform to preserve cash while it explored new strategic options. The new platform, "Researgency," is being developed through an exclusive license agreement with Younet AI. KALA BIO will initially be the first client, using the platform to analyze its own clinical program and biological data from its discontinued KPI-012 research before licensing it to other biotech and pharmaceutical companies. The on-premises model is a key differentiator, as it allows companies to use powerful AI tools on their own servers. This addresses a major security concern in the biotech industry, where proprietary biological data and trade secrets are among a company's most valuable assets. This move positions KALA BIO in the rapidly growing field of computational biology and bioinformatics, a career track that focuses on analyzing large biological datasets. This path is distinct from patient-facing roles in clinical research, which involve managing and running clinical trials to test new therapies. "Researgency" will include specialized AI agents designed for biomedical research tasks, such as analyzing protein interactions and modeling clinical trial outcomes. The goal is to create a recurring revenue stream by selling the platform as a service, targeting a market where the top 20 pharmaceutical companies invested approximately $167 billion in R&D in 2024. For students interested in the intersection of tech and life sciences, roles in this area often require skills in computer science, statistics, and biology. These "computational biologist" or "bioinformatics scientist" roles are central to modern drug discovery, helping to analyze the massive amounts of data generated from genomics and other research areas to identify new drug targets faster.
